|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 5 (March 1), 1999:
pp. 1477-1481
RAPID COMMUNICATION
Constitutive Degradation of PML/RAR Through the Proteasome Pathway
Mediates Retinoic Acid Resistance
Mirco Fanelli,
Saverio Minucci,
Vania Gelmetti,
Clara Nervi,
Carlo Gambacorti-Passerini, and
Pier Giuseppe Pelicci
From the European Institute of Oncology, the Department of
Experimental Oncology, Milan; Istituto Nazionale Tumori, Divisione
Oncologia Sperimentale D, Milan; Istituto di Clinica Medica I,
University of Perugia, Perugia; and Universita' `La Sapienza,"
Istituto di Istologia, Rome, Italy.
PML/RAR is the leukemogenetic protein of acute
promyelocytic leukemia (APL). Treatment with retinoic acid (RA) induces
degradation of PML/RAR, differentiation of leukaemic blasts, and
disease remission. However, RA resistance arises during RA treatment of APL patients. To investigate the phenomenon of RA resistance in APL, we
generated RA-resistant sublines from APL-derived NB4 cells. The
NB4.007/6 RA-resistant subline does not express the PML/RAR protein,
although its mRNA is detectable at levels comparable to those of the
parental cell line. In vitro degradation assays showed that the
half-life of PML/RAR is less than 30 minutes in NB4.007/6 and longer
than 3 hours in NB4. Treatment of NB4.007/6 cells with the proteasome
inhibitors LLnL and lactacystin partially restored
PML/RAR protein expression and resulted in a partial release of the
RA-resistant phenotype. Similarly, forced expression of PML/RAR, but
not RAR, into the NB4/007.6 cells restored sensitivity to RA
treatment to levels comparable to those of the NB4 cells. These results
indicate that constitutive degradation of PML/RAR protein may lead
to RA resistance and that PML/RAR expression is crucial to convey RA
sensitivity to APL cells.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. van Wageningen, M. C. Breems-de Ridder, J. Nigten, G. Nikoloski, C. A. J. Erpelinck-Verschueren, B. Lowenberg, T. de Witte, D. G. Tenen, B. A. van der Reijden, and J. H. Jansen
Gene transactivation without direct DNA binding defines a novel gain-of-function for PML-RAR{alpha}
Blood,
February 1, 2008;
111(3):
1634 - 1643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Quere, A. Baudet, B. Cassinat, G. Bertrand, J. Marti, L. Manchon, D. Piquemal, C. Chomienne, and T. Commes
Pharmacogenomic analysis of acute promyelocytic leukemia cells highlights CYP26 cytochrome metabolism in differential all-trans retinoic acid sensitivity
Blood,
May 15, 2007;
109(10):
4450 - 4460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Carbone, O. A. Botrugno, S. Ronzoni, A. Insinga, L. Di Croce, P. G. Pelicci, and S. Minucci
Recruitment of the Histone Methyltransferase SUV39H1 and Its Role in the Oncogenic Properties of the Leukemia-Associated PML-Retinoic Acid Receptor Fusion Protein
Mol. Cell. Biol.,
February 15, 2006;
26(4):
1288 - 1296.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood,
February 15, 2005;
105(4):
1669 - 1677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fanelli, A. Fantozzi, P. De Luca, S. Caprodossi, S.-i. Matsuzawa, M. A. Lazar, P. G. Pelicci, and S. Minucci
The Coiled-coil Domain Is the Structural Determinant for Mammalian Homologues of Drosophila Sina-mediated Degradation of Promyelocytic Leukemia Protein and Other Tripartite Motif Proteins by the Proteasome
J. Biol. Chem.,
February 13, 2004;
279(7):
5374 - 5379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Launay, M. Gianni, L. Diomede, L. M. Machesky, J. Enouf, and B. Papp
Enhancement of ATRA-induced cell differentiation by inhibition of calcium accumulation into the endoplasmic reticulum: cross-talk between RARalpha and calcium-dependent signaling
Blood,
April 15, 2003;
101(8):
3220 - 3228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res.,
July 15, 2002;
62(14):
3893 - 3903.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-C. Zhou, S. H. Kim, W. Ding, C. Schultz, R. P. Warrell Jr, and R. E. Gallagher
Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo
Blood,
February 15, 2002;
99(4):
1356 - 1363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gianni', Y. Kalac, I. Ponzanelli, A. Rambaldi, M. Terao, and E. Garattini
Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RAR{alpha} and PML-RAR{alpha}
Blood,
May 15, 2001;
97(10):
3234 - 3243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wang, X. Zheng, F. G. Behm, and M. Ratnam
Differentiation-independent retinoid induction of folate receptor type beta , a potential tumor target in myeloid leukemia
Blood,
November 15, 2000;
96(10):
3529 - 3536.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Gambacorti-Passerini, R. Barni, P. le Coutre, M. Zucchetti, G. Cabrita, L. Cleris, F. Rossi, E. Gianazza, J. Brueggen, R. Cozens, et al.
Role of {alpha}1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571
J Natl Cancer Inst,
October 18, 2000;
92(20):
1641 - 1650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Shao, A. Rosenauer, K. Mann, C.-P. B. Chang, C. Rachez, L. P. Freedman, and W. H. Miller Jr
Ligand-inducible interaction of the DRIP/TRAP coactivator complex with retinoid receptors in retinoic acid-sensitive and -resistant acute promyelocytic leukemia cells
Blood,
September 15, 2000;
96(6):
2233 - 2239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rego, L.-Z. He, R. P. Warrell Jr., Z.-G. Wang, and P. P. Pandolfi
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
PNAS,
August 17, 2000;
(2000)
180290497.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J. Zhu, M. Gianni, E. Kopf, N. Honore, M. Chelbi-Alix, M. Koken, F. Quignon, C. Rochette-Egly, and H. de The
Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha ) and oncogenic RARalpha fusion proteins
PNAS,
December 21, 1999;
96(26):
14807 - 14812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Wojcik, I. Mlynarczuk, G. Hoser, J. Kawiak, T. Stoklosa, J. Golab, and S. Wilk
A Combination of Retinoic Acid and Proteasome Inhibitors for the Treatment of Leukemias Is Potentially Dangerous
Blood,
September 1, 1999;
94(5):
1827 - 1828.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Naoe, K. Kitamura;, M. Fanelli, and P. G. Pelicci
Relationship Between Degradation of PML-RARalpha and Differentiation
Blood,
August 15, 1999;
94(4):
1478 - 1479.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Rego, L.-Z. He, R. P. Warrell Jr., Z.-G. Wang, and P. P. Pandolfi
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins
PNAS,
August 29, 2000;
97(18):
10173 - 10178.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
